Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) EBT Margin (2016 - 2025)

Protalix BioTherapeutics has reported EBT Margin over the past 16 years, most recently at 2.16% for Q4 2025.

  • Quarterly results put EBT Margin at 2.16% for Q4 2025, down 6728.0% from a year ago — trailing twelve months through Dec 2025 was 1.95% (down 1825.0% YoY), and the annual figure for FY2025 was 1.95%, down 1825.0%.
  • EBT Margin for Q4 2025 was 2.16% at Protalix BioTherapeutics, down from 12.54% in the prior quarter.
  • Over the last five years, EBT Margin for PLX hit a ceiling of 65.12% in Q4 2024 and a floor of 210.31% in Q4 2023.
  • Median EBT Margin over the past 5 years was 27.89% (2022), compared with a mean of 37.98%.
  • Biggest five-year swings in EBT Margin: tumbled -17306bps in 2023 and later skyrocketed 27543bps in 2024.
  • Protalix BioTherapeutics' EBT Margin stood at 77.37% in 2021, then soared by 52bps to 37.25% in 2022, then crashed by -465bps to 210.31% in 2023, then soared by 131bps to 65.12% in 2024, then plummeted by -103bps to 2.16% in 2025.
  • The last three reported values for EBT Margin were 2.16% (Q4 2025), 12.54% (Q3 2025), and 4.22% (Q2 2025) per Business Quant data.